a 66

A66 is a specific and effective p110α inhibitor(IC50=32 nM).

SH-E4A-66 is a C2-COUPLr (COvalent Protein Ligators) featuring a carbazole skeleton, which does not include heterogeneous cysteine-reactive warheads such as acrylamide and chloroacetamide. This compound effectively couples with EML4-ALK (EC50=1.5 μM) and inhibits the kinase activity of EML4-ALK (IC50=2.3 µM).

Synta66 is a store-operated calcium entry channel Orai inhibitor, and used for the research of neurological disease.

DC_C66 DC_C66 has good selectivity for CARM1, PRMT1 (IC50 = 21μM), PRMT6 (IC50 = 47μM) and PRMT5. It is a cell-permeable, selective co-activator related arginine methyltransferase 1 (CARM1) inhibitor with IC50 of 1.8 μM.

MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.

NLRP3-IN-66 (example 257) is a potent inhibitor of the NLRP3 inflammasome.

Antiproliferative agent-66 (Compound B3) is an antiproliferative compound that induces apoptosis and causes cell cycle arrest. It demonstrates IC50 values ranging from 2.03 to 3.6 µM against SH-SY5Y neuroblastoma, HT-29 colorectal adenocarcinoma, and fibroblasts. Additionally, Antiproliferative agent-66 functions as a microtubule polymerization inhibitor with an IC50 of 0.79 µM.

E3ligaseLigand 66 is an E3 ligase ligand that facilitates the recruitment of IAP proteins. It can be linked with SARS-CoV-2 Mpro ligand 1 via a linker to form PROTACBP-198.

Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory properties. It inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice.

HDAC-IN-66 (compound 2F) is a selective inhibitor of HDAC and a derivative of Pomalidomide, effectively inhibiting hematological tumor cells.

E3ligaseLigand-Linker Conjugate 66 is a conjugate composed of an E3 ligase ligand and a linker, specifically formed from Thalidomide and its corresponding linker. It functions as a Cereblon ligand, recruiting the CRBN protein and serving as a crucial intermediate in the synthesis of complete PROTACs molecules.

NZ-66 is a chimeric molecule that targets UNC-51-like kinase 1 (ULK1) to facilitate proximity-induced, ULK1-dependent mitochondrial degradation. It triggers mitophagy (mitochondrial autophagy) and has potential for alleviating neurodegenerative diseases.

BAK2-66 is a selective antagonist of the dopamine D3 receptor.

Antitumor agent-66 (Compound 4) is a derivative of (-)-cleistenolide, exhibiting potential as a research tool for cancer diseases [1].

Antibacterial agent 66 (Compound 6q) is a trifluoromethylpyridine 1,3,4-oxadiazole derivative active against Xanthomonas oryzae pv. oryzae (Xoo) (EC50: 7.2 μg/mL).

ZLM-66 is a doravirine analogue and a potent inhibitor of non-nucleoside reverse transcriptases (NNRTIs), acting on wild-type HIV-1 reverse transcriptase (IC50: 41 nM), wild-type HIV-1 (EC50: 13 nM) and cIAP1 (EC50: 0.32 nM). ZLM-66 can be used in AIDS research.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

SARS-CoV-2-IN-66 (1), a derivative of vitamin K, serves as an inhibitor of SARS-CoV-2, with an effective concentration (EC50) of 70.8 μM in VeroE6/TMPRSS2 cells [1].

HSD17B13-IN-66 (Compound 146), an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), shows a potent IC 50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research pertaining to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1].

MB-66 (MAPP-66) is a fully human IgG1 antibody targeting HSV and HIV. It is a monoclonal antibody membrane intended for vaginal application. The isotype control for MB-66 can be referred to as HumanIgG1kappa, Isotype Control.

CEF1, Influenza Matrix Protein M1 (58-66), is an epitope derived from the matrix protein of the influenza A virus. GILGFVFTL is an HLA-A2-restricted epitope from this matrix M1 protein.

Antiviralagent 66 (Compound 60) serves as an inhibitor of filoviruses (Filovirus), effectively suppressing pseudoviruses of Ebola, Marburg, Zaire, Sudan, Bundibugyo, Reston, and Tai Forest, with EC50 values of 0.16, 2.24, 0.16, 0.89, 0.21, 0.21, and 0.11 μM, respectively.

VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.

HIV-1inhibitor-66 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits inhibitory activity against wild-type HIV-1 reverse transcriptase (HIV-1 reverse transcriptase) with an IC50 of 40 nM.